Norwich, CT, United States of America

Ravi Chari

This inventor holds 23 USPTO granted patents and 15 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Antibody-Drug Conjugates. Top assignees: Immunogen, Inc., Abbvie Inc., Regeneron Pharmaceuticals, Inc.. Active years: 1993-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ravi Chari. Retrieved from https://idiyas.com/inventor/ravi-chari

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 4.6

ph-index = 11

Forward Citations = 2,116(Granted Patents)


Location History:

  • Boston, MA (US) (1993 - 1995)
  • Brookline, MA (US) (1993 - 1995)
  • St. Newton, MA (US) (1998)
  • Worcester, MA (US) (2015 - 2018)
  • Newton, MA (US) (1995 - 2022)
  • Norwich, CT (US) (2016 - 2024)

Company Filing History:


Years Active: 1993-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Antibody-Drug Conjugates
Lyophilized Drug Products
Cytotoxic Agents
Maytansinoids
Cell-Binding Agents
Benzodiazepine Derivatives
IL-1 Binding Proteins
Platelet-Derived Growth Factor
Dual Variable Domain Immunoglobulin
Targeted Delivery
Cyclopropylbenzindole
23 patents (USPTO):Explore Patents

Title: The Innovative Mind of Ravi Chari in Pharmaceuticals

Introduction

Ravi Chari, an accomplished inventor based in Norwich, CT, has made significant contributions to the field of pharmaceuticals, particularly in the area of lyophilization. With a portfolio of 11 patents, his work focuses on developing innovative methods and formulations that enhance the stability and shelf life of drug products.

Latest Patents

Among his latest innovations is a patent related to target residual moisture content for lyophilized drug products. This patent outlines lyophilization methods which allow for the preparation of protein formulations that can be stored at room temperature for long-term stability or improved refrigeration storage. The invention specifically addresses the achievement of a target percentage of residual moisture, ideally between 3-5%. Furthermore, it details a process for controlling the rate of desorption during secondary drying, which can maintain a temperature similar to that of the primary drying shelf temperature. Notably, this method can also be executed without a distinct secondary drying step, showcasing the flexibility and efficacy of Chari's approach.

Career Highlights

Ravi Chari's career is highlighted by his tenure at leading pharmaceutical companies, including AbbVie Inc. and Zoetis Belgium S.A. His experience in these prestigious organizations has equipped him with a profound understanding of drug formulation and stability, enabling him to develop cutting-edge pharmaceutical innovations.

Collaborations

Throughout his career, Ravi has collaborated with esteemed professionals such as Susan E. Lacy and Meha Chhaya. These partnerships have likely influenced his inventive processes and allowed for the exchange of invaluable knowledge in the pharmaceutical domain.

Conclusion

Ravi Chari stands out as a prominent inventor whose work in lyophilization demonstrates a commitment to advancing pharmaceutical science. With his innovative methodologies and team collaborations, he continues to pave the way for improved drug formulation techniques, ensuring better stability and accessibility for essential medications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…